An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women with a History of Pancreatitis - ECLIPSEIV

Study identifier:D5880C00003

ClinicalTrials.gov identifier:NCT02189252

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomized, Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy, and Safety of Epanova® and Lovaza® in Men and Women with a History of Pancreatitis

Medical condition

severe hypertriglyceridemia

Phase

Phase 1

Healthy volunteers

No

Study drug

Epanova, Lovaza

Sex

All

Actual Enrollment

30

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 01 Oct 2014
Primary Completion Date: 01 Jul 2015
Study Completion Date: 01 Jul 2015

Study design

Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 May 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria